OGI vs. GALT, OVID, CDT, MACK, QURE, RENB, PRLD, ACRV, FHTX, and XBIT
Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Galectin Therapeutics (GALT), Ovid Therapeutics (OVID), Conduit Pharmaceuticals (CDT), Merrimack Pharmaceuticals (MACK), uniQure (QURE), Renovaro (RENB), Prelude Therapeutics (PRLD), Acrivon Therapeutics (ACRV), Foghorn Therapeutics (FHTX), and XBiotech (XBIT). These companies are all part of the "pharmaceutical preparations" industry.
Galectin Therapeutics (NASDAQ:GALT) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings.
Galectin Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Organigram has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.
Galectin Therapeutics has a net margin of 0.00% compared to Galectin Therapeutics' net margin of -173.48%. Organigram's return on equity of 0.00% beat Galectin Therapeutics' return on equity.
11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Organigram shares are owned by institutional investors. 52.7% of Galectin Therapeutics shares are owned by insiders. Comparatively, 0.1% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Galectin Therapeutics has higher earnings, but lower revenue than Organigram. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.
Galectin Therapeutics received 148 more outperform votes than Organigram when rated by MarketBeat users. However, 70.61% of users gave Organigram an outperform vote while only 60.31% of users gave Galectin Therapeutics an outperform vote.
Galectin Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 228.36%. Given Organigram's higher probable upside, equities analysts clearly believe Galectin Therapeutics is more favorable than Organigram.
In the previous week, Galectin Therapeutics' average media sentiment score of 1.00 beat Organigram's score of 0.50 indicating that Organigram is being referred to more favorably in the news media.
Summary
Galectin Therapeutics and Organigram tied by winning 7 of the 14 factors compared between the two stocks.
Get Organigram News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organigram Competitors List
Related Companies and Tools
